Roche, obesity and Zealand Pharma
No. 4 / 2025Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...
Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...
Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its ...
4d
GlobalData on MSNZealand and Roche strike $5.3bn obesity treatment dealThe two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.
Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be ...
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results